Antegrin pivots in IPF with 'breakthrough' in oral formulation
By Marie Powers
Tuesday, April 12, 2016
One of the most formidable challenges facing start-ups indeed, facing the drug development community as a whole is how to translate a promising scientific approach into a therapy that's not only safe and effective but easy to use.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.